Why Johnson & Johnson (JNJ), United Health (UNH) And Procter & Gamble (PG) Are Holding the S&P 500 From Dropping More24/7 Wall Street • 03/31/25
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung CancerZacks Investment Research • 03/31/25
Procter & Gamble, Johnson & Johnson Among 10 Companies To Announce Dividend Increases In First Half Of AprilSeeking Alpha • 03/30/25
These 10 Stocks Have Increased Dividends For Over 60 Consecutive Years. Should You Buy Them Now?24/7 Wall Street • 03/30/25
Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)Seeking Alpha • 03/28/25
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply ChainInvestors Business Daily • 03/27/25
Strategically Building A $100,000 Dividend Portfolio For Attractive Income And Strong Risk-Adjusted ReturnsSeeking Alpha • 03/26/25
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancerPRNewsWire • 03/26/25
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)PRNewsWire • 03/26/25
Here's How to Play JNJ Stock as it Announces $55B US Investment PlanZacks Investment Research • 03/24/25
2 Dividend Picks Yielding Up To 5.67% For A Balanced Income & Growth PortfolioSeeking Alpha • 03/22/25
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four YearsBusiness Wire • 03/21/25